Efficacy and safety of atropine at different concentrations in prevention of myopia progression in Asian children: a systematic review and Meta-analysis of randomized clinical trials
Rattachement africain : cn. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
AIM: To assess the efficacy versus the adverse effects of various concentrations of atropine in the prevention of myopia in Asian children. METHODS: Databases (PubMed, EMBASE, the Cochrane Library and Web of science) were comprehensively searched from inception to April 2022. Types of studies included were randomized clinical trials (RCTs). The published languages were limited to English. Two researchers assessed the quality of included studies independently using Cochrane risk of bias tool based on the Cochrane Handbook for Systematic Reviews of Interventions. Funnel plots and Egger’s test were used for detection of publication bias. Meta-analyses were conducted using STATA (version 15.0; StataCorp). RESULTS: A total of 15 RCTs involving 2268 patients were included in the study. In the atropine group, spherical equivalent progressed at a significantly lower rate [weighted mean difference (WMD)=0.39, 95% confidence interval (CI): 0.23, 0.54] than in the control group. A WMD of 0.15 mm was associated with less axial elongation (95%CI -0.19, -0.10). Different doses showed statistically significant differences (P<0.05) and an improved effect could result from a higher concentration. Changes in photopic pupil size and mesopic pupil size in atropine group is 0.70 mm (95%CI: 0.33, 1.06) and 0.38 mm (95%CI: 0.22, 0.54) more than the control group. In the present Meta-analysis, no changes in accommodative amplitude (AA) were associated with atropine administration. Atropine administration increased the risk of adverse effects by 1.37 times. CONCLUSION: Concentrations of less than 1% atropine are able to effectively retard diopter and axis growth of myopia in Asian children in a dose-dependent manner. Meanwhile, it caused pupil enlargement, but induced no change in the AA within this range. Further study is required to determine the dosage needed to achieve maximum efficacy and minimal side effects.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Efficacy and safety of atropine at different concentrations in prevention of myopia progression in Asian children: a systematic review and Meta-analysis of randomized clinical trials
- Date Crossref
- 18/08/2023
- Éditeur
- Press of International Journal of Ophthalmology (IJO Press)
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Xijing Hospital pays non établi dans la noticeÉtablissement de santé
-
Air Force Medical University pays non établi dans la noticeUniversité ou école supérieure
-
Soochow University Department of Ophthalmology pays non établi dans la noticeUniversité ou école supérieure
-
Second Affiliated Hospital of Soochow University pays non établi dans la noticeÉtablissement de santé
-
Sun Yat-sen University pays non établi dans la noticeUniversité ou école supérieure
-
Fourth Military Medical University Department of Ophthalmology pays non établi dans la noticeUniversité ou école supérieure
-
Eye Institute of Chinese PLA Department of Ophthalmology pays non établi dans la noticeStructure de recherche
-
Zhongshan School of Medicine pays non établi dans la noticeUniversité ou école supérieure
-
the People's Liberation Army 988th Hospital Department of Ophthalmology pays non établi dans la noticeÉtablissement de santé
Xijing Hospital, Air Force Medical University et Department of Ophthalmology — Soochow University, avec 6 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.